Synergistic anti-cancer effect of baicalein and silymarin on human hepatoma HepG2 Cells. 2009

Ching-Hsein Chen, and Tien-Shang Huang, and Chung-Hang Wong, and Chian-Lang Hong, and Yung-Hong Tsai, and Chia-Ching Liang, and Fung-Jou Lu, and Wen-Huei Chang
Graduate Institute of Biomedical and Biopharmaceutical Sciences, College of Life Sciences, National Chiayi University, 300 Syuefu Road, Chiayi 600, Taiwan.

This study investigated the effect of baicalein, silymarin, and their combination, on two human liver-derived cell lines, HepG2 (hepatocellular carcinoma) and Chang liver (non-tumor liver cells). It was found that 6.75 microg/ml baicalein or 100 microg/ml silymarin alone significantly inhibited the growth of HepG2. When baicalein was used in combination with silymarin on HepG2, an additive effect at 24 h and a synergistic effect at 48 h were observed. The viability at 48 h was 85.62% from 6.75 microg/ml baicalein treatment; but the viability reduced to 49.67%, 38.56%, and 19.61% when 25, 50, and 100 microg/ml silymarin respectively, was added to the treatment. By contrast, each treatment had little or no effect on Chang liver. Compared to treatment of baicalein or silymarin alone on HepG2, combination of both drugs synergistically increased the percentages of cells in G0/G1 phase and decreased those in S-phase, which were associated with up-regulation of Rb, p53, p21(Cip1) and p27(Kip1) and down-regulation of cyclin D1, cyclin E, CDK4 and phospho-Rb. The results indicate that the combination of baicalein and silymarin eradicates tumor cells efficiently, has minimal deleterious effects to the surrounding normal cells, and offers mechanistic insight for further exploitation of HCC treatment.

UI MeSH Term Description Entries
D008113 Liver Neoplasms Tumors or cancer of the LIVER. Cancer of Liver,Hepatic Cancer,Liver Cancer,Cancer of the Liver,Cancer, Hepatocellular,Hepatic Neoplasms,Hepatocellular Cancer,Neoplasms, Hepatic,Neoplasms, Liver,Cancer, Hepatic,Cancer, Liver,Cancers, Hepatic,Cancers, Hepatocellular,Cancers, Liver,Hepatic Cancers,Hepatic Neoplasm,Hepatocellular Cancers,Liver Cancers,Liver Neoplasm,Neoplasm, Hepatic,Neoplasm, Liver
D002453 Cell Cycle The complex series of phenomena, occurring between the end of one CELL DIVISION and the end of the next, by which cellular material is duplicated and then divided between two daughter cells. The cell cycle includes INTERPHASE, which includes G0 PHASE; G1 PHASE; S PHASE; and G2 PHASE, and CELL DIVISION PHASE. Cell Division Cycle,Cell Cycles,Cell Division Cycles,Cycle, Cell,Cycle, Cell Division,Cycles, Cell,Cycles, Cell Division,Division Cycle, Cell,Division Cycles, Cell
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004357 Drug Synergism The action of a drug in promoting or enhancing the effectiveness of another drug. Drug Potentiation,Drug Augmentation,Augmentation, Drug,Augmentations, Drug,Drug Augmentations,Drug Potentiations,Drug Synergisms,Potentiation, Drug,Potentiations, Drug,Synergism, Drug,Synergisms, Drug
D005434 Flow Cytometry Technique using an instrument system for making, processing, and displaying one or more measurements on individual cells obtained from a cell suspension. Cells are usually stained with one or more fluorescent dyes specific to cell components of interest, e.g., DNA, and fluorescence of each cell is measured as it rapidly transverses the excitation beam (laser or mercury arc lamp). Fluorescence provides a quantitative measure of various biochemical and biophysical properties of the cell, as well as a basis for cell sorting. Other measurable optical parameters include light absorption and light scattering, the latter being applicable to the measurement of cell size, shape, density, granularity, and stain uptake. Cytofluorometry, Flow,Cytometry, Flow,Flow Microfluorimetry,Fluorescence-Activated Cell Sorting,Microfluorometry, Flow,Cell Sorting, Fluorescence-Activated,Cell Sortings, Fluorescence-Activated,Cytofluorometries, Flow,Cytometries, Flow,Flow Cytofluorometries,Flow Cytofluorometry,Flow Cytometries,Flow Microfluorometries,Flow Microfluorometry,Fluorescence Activated Cell Sorting,Fluorescence-Activated Cell Sortings,Microfluorimetry, Flow,Microfluorometries, Flow,Sorting, Fluorescence-Activated Cell,Sortings, Fluorescence-Activated Cell
D006528 Carcinoma, Hepatocellular A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested. Hepatocellular Carcinoma,Hepatoma,Liver Cancer, Adult,Liver Cell Carcinoma,Liver Cell Carcinoma, Adult,Adult Liver Cancer,Adult Liver Cancers,Cancer, Adult Liver,Cancers, Adult Liver,Carcinoma, Liver Cell,Carcinomas, Hepatocellular,Carcinomas, Liver Cell,Cell Carcinoma, Liver,Cell Carcinomas, Liver,Hepatocellular Carcinomas,Hepatomas,Liver Cancers, Adult,Liver Cell Carcinomas
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D012838 Silymarin A mixture of flavonoids extracted from seeds of the MILK THISTLE, Silybum marianum. It consists primarily of silybin and its isomers, silicristin and silidianin. Silymarin displays antioxidant and membrane stabilizing activity. It protects various tissues and organs against chemical injury, and shows potential as an antihepatoxic agent. Carsil,Karsil,Legalon,Silimarin
D044950 Flavanones A group of FLAVONOIDS characterized with a 4-ketone. 2-Phenyl-Benzopyran-4-Ones,2 Phenyl Benzopyran 4 Ones

Related Publications

Ching-Hsein Chen, and Tien-Shang Huang, and Chung-Hang Wong, and Chian-Lang Hong, and Yung-Hong Tsai, and Chia-Ching Liang, and Fung-Jou Lu, and Wen-Huei Chang
January 2012, Molecular medicine reports,
Ching-Hsein Chen, and Tien-Shang Huang, and Chung-Hang Wong, and Chian-Lang Hong, and Yung-Hong Tsai, and Chia-Ching Liang, and Fung-Jou Lu, and Wen-Huei Chang
January 2016, International journal of nanomedicine,
Ching-Hsein Chen, and Tien-Shang Huang, and Chung-Hang Wong, and Chian-Lang Hong, and Yung-Hong Tsai, and Chia-Ching Liang, and Fung-Jou Lu, and Wen-Huei Chang
January 2012, The American journal of Chinese medicine,
Ching-Hsein Chen, and Tien-Shang Huang, and Chung-Hang Wong, and Chian-Lang Hong, and Yung-Hong Tsai, and Chia-Ching Liang, and Fung-Jou Lu, and Wen-Huei Chang
August 2012, Asian Pacific journal of tropical biomedicine,
Ching-Hsein Chen, and Tien-Shang Huang, and Chung-Hang Wong, and Chian-Lang Hong, and Yung-Hong Tsai, and Chia-Ching Liang, and Fung-Jou Lu, and Wen-Huei Chang
May 2013, Wei sheng yan jiu = Journal of hygiene research,
Ching-Hsein Chen, and Tien-Shang Huang, and Chung-Hang Wong, and Chian-Lang Hong, and Yung-Hong Tsai, and Chia-Ching Liang, and Fung-Jou Lu, and Wen-Huei Chang
June 2014, Letters in applied microbiology,
Ching-Hsein Chen, and Tien-Shang Huang, and Chung-Hang Wong, and Chian-Lang Hong, and Yung-Hong Tsai, and Chia-Ching Liang, and Fung-Jou Lu, and Wen-Huei Chang
September 2007, Cell biology international,
Ching-Hsein Chen, and Tien-Shang Huang, and Chung-Hang Wong, and Chian-Lang Hong, and Yung-Hong Tsai, and Chia-Ching Liang, and Fung-Jou Lu, and Wen-Huei Chang
March 2011, European journal of pharmacology,
Ching-Hsein Chen, and Tien-Shang Huang, and Chung-Hang Wong, and Chian-Lang Hong, and Yung-Hong Tsai, and Chia-Ching Liang, and Fung-Jou Lu, and Wen-Huei Chang
May 2009, Electrophoresis,
Ching-Hsein Chen, and Tien-Shang Huang, and Chung-Hang Wong, and Chian-Lang Hong, and Yung-Hong Tsai, and Chia-Ching Liang, and Fung-Jou Lu, and Wen-Huei Chang
January 2014, African journal of traditional, complementary, and alternative medicines : AJTCAM,
Copied contents to your clipboard!